Next, we examined whether the expression levels of these genes were correlated with responsiveness to sorafenib in a cohort of 67 patients with HCC who received sorafenib therapy via the Gene Expression Omnibus (GEO) dataset GSE109211.[13] The results revealed that patients with HCC who were non‐responsive to sorafenib treatment had higher levels of COPS5, ZRANB2, or TSPAN17 than those who responded well to sorafenib (Figure 1G; Figure S1C, Supporting Information). This evidence concerns the gene ZRANB2 and hepatocellular carcinoma.